Reply

Jesús Quintero, Cristina Molera, Javier Juamperez, Susanna Redecillas, Silvia Meavilla, Raquel Nuñez, Camila García‐Volpe, Mireia del Toro, Ángels Garcia‐Cazorla, Juan Ortega, Óscar Segarra, Javier Martin de Carpi, Itxarone Bilbao, Ramon Charco – 24 November 2018

Diagnosis and Treatment of Alcohol Use Disorder in Patients With End‐Stage Alcoholic Liver Disease

Fabio Caputo, Marco Domenicali, Mauro Bernardi – 24 November 2018 – Between 14%‐30% of the world’s population is affected by alcohol use disorder (AUD), and excessive alcohol consumption represents the most common cause of liver disease in the western world. The clinical picture of alcoholic end‐stage liver disease is rendered extremely complex, as manifestations such as alcohol withdrawal syndrome, craving and physical dependence, as well as extrahepatic alcohol‐related diseases merge with the complications of advanced cirrhosis.

Sexual Dysfunction and Sex Hormone Abnormalities in Patients With Cirrhosis: Review of Pathogenesis and Management

Shuet Fong Neong, Emma O. Billington, Stephen E. Congly – 23 November 2018 – Healthy sexual function is important to maintain a good quality of life but is frequently impaired in patients with cirrhosis. The degree of sexual dysfunction appears to be linked with the degree of hepatic dysfunction. In men, sexual dysfunction can be related to the hyperestrogenism of portal hypertension and/or to decreased testosterone resulting from testicular dysfunction.

Sexual Dysfunction and Sex Hormone Abnormalities in Patients With Cirrhosis: Review of Pathogenesis and Management

Shuet Fong Neong, Emma O. Billington, Stephen E. Congly – 23 November 2018 – Healthy sexual function is important to maintain a good quality of life but is frequently impaired in patients with cirrhosis. The degree of sexual dysfunction appears to be linked with the degree of hepatic dysfunction. In men, sexual dysfunction can be related to the hyperestrogenism of portal hypertension and/or to decreased testosterone resulting from testicular dysfunction.

Genes and Pathways Promoting Long‐Term Liver Repopulation by Ex Vivo hYAP‐ERT2 Transduced Hepatocytes and Treatment of Jaundice in Gunn Rats

Esther A. Peterson, Zsuzsanna Polgar, Gnanapackiam S. Devakanmalai, Yanfeng Li, Fadi L. Jaber, Wei Zhang, Xia Wang, Niloy J. Iqbal, John W. Murray, Namita Roy‐Chowdhury, Wilber Quispe‐Tintaya, Alexander Y. Maslov, Tatyana L. Tchaikovskaya, Yogeshwar Sharma, Leslie E. Rogler, Sanjeev Gupta, Liang Zhu, Jayanta Roy‐Chowdhury, David A. Shafritz – 20 November 2018 – Hepatocyte transplantation is an attractive alternative to liver transplantation. Thus far, however, extensive liver repopulation by adult hepatocytes has required ongoing genetic, physical, or chemical injury to host liver.

Con: The Unclear Benefit of Albumin

Alastair O’Brien – 17 November 2018 – Many studies have shown that 20% human albumin solution infusions improve circulatory function in patients with advanced liver disease, and this treatment is widely recommended and used by all hepatologists. However, it is more expensive than other crystalloids or colloids, and several countries suffer shortages of supply. This article examines whether other fluids might be considered for these patients.

Hepatitis B Treatment: What We Know Now and What Remains to Be Researched

Anna Suk‐Fong Lok – 15 November 2018 – Chronic hepatitis B virus (HBV) infection remains a major global health burden. Currently, two types of treatment, interferons (IFNs) and nucleos(t)ide analogues (NAs), have been approved. These treatments are effective in suppressing HBV replication and in decreasing the risk of developing cirrhosis, liver failure, hepatocellular carcinoma (HCC), and death. However, these treatments do not eliminate the virus, and the risk of HCC remains.

Chloroquine Is Effective for Maintenance of Remission in Autoimmune Hepatitis: Controlled, Double‐Blind, Randomized Trial

Débora Raquel Benedita Terrabuio, Marcio Augusto Diniz, Lydia Teofilo de Moraes Falcão, Ana Luiza Vilar Guedes, Larissa Akeme Nakano, Andréia Silva Evangelista, Fabiana Roberto Lima, Clarice Pires Abrantes‐Lemos, Flair José Carrilho, Eduardo Luiz Rachid Cancado – 14 November 2018 – Between 50% and 86% of patients with autoimmune hepatitis (AIH) relapse after immunosuppression withdrawal; long‐term immunosuppression is associated with increased risk of neoplasias and infections.

Subscribe to